Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)

Opinion
Video

Ajai Chari, MD, presents the case of a 71-year-old woman with relapsed/refractory multiple myeloma who showed signs of disease progression after four lines of therapy and was initiated on a recently FDA-approved bispecific antibody, talquetamab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      Overcoming Obstacles in Prescribing High-Cost Myeloma Therapies
      Overcoming Obstacles in Prescribing High-Cost Myeloma Therapies
      4 experts are featured in this series.
      Future Outlooks for CAR T in Early R/R Multiple Myeloma
      4 experts are featured in this series.
      KarMMa-3 Trial: Additional Insights From Ide-Cel in RRMM
      4 experts are featured in this series.
      KarMMa-3 Highlights: Ide-Cel vs Standard Regimens in Triple-Class– Exposed RRMM
      Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall
      Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall
      4 experts are featured in this series.
      Patient Case 5: A 66-Year-Old Patient With R/R MM With Relapse Less Than 2 Years Post ASCT—Next Steps
      4 experts are featured in this series.
      CARTITUDE-4: Navigating Late CAR-T Toxicities
      4 experts are featured in this series.
      CARTITUDE-4 Highlights: Cilta-Cel vs Standard of Care in R/R MM
      4 experts are featured in this series.
      Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting
      4 experts are featured in this series.
      Patient Case 4: A 38-Year-Old Woman With Functional High-Risk MM With Progressive Disease at Day 60 Post ASCT—Next Treatment Approaches
      Related Content
      Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

      Italian Study Highlights Real-World Data for Melphalan Flufenamide in Myeloma

      Jason M. Broderick
      April 17th 2025
      Article

      Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its approval of the treatment last year.

      Read More

      Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

      Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

      Binod Dhakal, MD, MS;Jordyn Sava
      June 14th 2024
      Podcast

      In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

      Listen

      Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

      Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

      Tony Berberabe, MPH
      April 11th 2025
      Article

      A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

      Read More

      Advancing Myeloma Treatment With Blood-Based MRD Testing

      Advancing Myeloma Treatment With Blood-Based MRD Testing

      Jordyn Sava;Ben Derman, MD
      February 15th 2024
      Podcast

      In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

      Listen

      Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

      Teclistamab Combo Yields Deep Responses in Newly Diagnosed Myeloma

      Jordyn Sava
      April 10th 2025
      Article

      Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

      Read More

      Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

      Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

      Targeted Oncology Staff
      April 8th 2025
      Article

      During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

      Read More